Avalyn Pharma Acquired | Healthcare M&A Deal

Avalyn Pharma has completed the acquisition of Avalyn Pharma, a healthcare services other business in California, for $300M. Avalyn Pharma develops inhalable drug candidates for pulmonary fibrosis, targeting two lung indications through ongoing clinical programs. The company’s pipeline is designed to support future lung drug trials, with key mid-stage study data expected in 2027. The announced other acquisition is structured as an IPO cash raise to fund development, reflecting healthcare M&A interest in respiratory therapeutics and inhalation delivery.